About 9% and 6% were on sulfonylureas and GLP-1R agonists, respectively, while less than 5% were on DPP-4 and SGLT2 inhibitors, respectively
For most patients using pen devices with 4mm needles, a 90-degree angle is appropriate
The MDWatch teams dedication and encouragement have truly changed my life, and I couldnt be more grateful for the lasting impact this program has had on my health and well-being
Effects of laparoscopic Roux-en-Y gastric bypass on bone mineral density and markers of bone turnover
Bakuchiol: Often referred to as a natural alternative to retinol, Bakuchiol delivers powerful smoothing and anti-wrinkle benefits, without the irritation that can come with traditional retinoids
CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage
